
Global Maternal Pertussis Vaccine for Newborn Protection Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Maternal Pertussis Vaccine for Newborn Protection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Maternal Pertussis Vaccine for Newborn Protection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Maternal Pertussis Vaccine for Newborn Protection market include Zhifei Biological, Walvax, Minhai Biological, GlaxoSmithKline, Sanofi Pasteur and Intravacc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Maternal Pertussis Vaccine for Newborn Protection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Maternal Pertussis Vaccine for Newborn Protection, also provides the sales of main regions and countries. Of the upcoming market potential for Maternal Pertussis Vaccine for Newborn Protection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Maternal Pertussis Vaccine for Newborn Protection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Maternal Pertussis Vaccine for Newborn Protection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Maternal Pertussis Vaccine for Newborn Protection sales, projected growth trends, production technology, application and end-user industry.
Maternal Pertussis Vaccine for Newborn Protection Segment by Company
Zhifei Biological
Walvax
Minhai Biological
GlaxoSmithKline
Sanofi Pasteur
Intravacc
Maternal Pertussis Vaccine for Newborn Protection Segment by Type
Whole-cell Pertussis Vaccine
Acellular Pertussis Vaccine
Maternal Pertussis Vaccine for Newborn Protection Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Maternal Pertussis Vaccine for Newborn Protection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Maternal Pertussis Vaccine for Newborn Protection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Maternal Pertussis Vaccine for Newborn Protection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Maternal Pertussis Vaccine for Newborn Protection significant trends, drivers, influence factors in global and regions.
6. To analyze Maternal Pertussis Vaccine for Newborn Protection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Maternal Pertussis Vaccine for Newborn Protection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Maternal Pertussis Vaccine for Newborn Protection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Maternal Pertussis Vaccine for Newborn Protection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Maternal Pertussis Vaccine for Newborn Protection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Maternal Pertussis Vaccine for Newborn Protection industry.
Chapter 3: Detailed analysis of Maternal Pertussis Vaccine for Newborn Protection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Maternal Pertussis Vaccine for Newborn Protection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Maternal Pertussis Vaccine for Newborn Protection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Maternal Pertussis Vaccine for Newborn Protection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Maternal Pertussis Vaccine for Newborn Protection market include Zhifei Biological, Walvax, Minhai Biological, GlaxoSmithKline, Sanofi Pasteur and Intravacc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Maternal Pertussis Vaccine for Newborn Protection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Maternal Pertussis Vaccine for Newborn Protection, also provides the sales of main regions and countries. Of the upcoming market potential for Maternal Pertussis Vaccine for Newborn Protection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Maternal Pertussis Vaccine for Newborn Protection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Maternal Pertussis Vaccine for Newborn Protection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Maternal Pertussis Vaccine for Newborn Protection sales, projected growth trends, production technology, application and end-user industry.
Maternal Pertussis Vaccine for Newborn Protection Segment by Company
Zhifei Biological
Walvax
Minhai Biological
GlaxoSmithKline
Sanofi Pasteur
Intravacc
Maternal Pertussis Vaccine for Newborn Protection Segment by Type
Whole-cell Pertussis Vaccine
Acellular Pertussis Vaccine
Maternal Pertussis Vaccine for Newborn Protection Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Maternal Pertussis Vaccine for Newborn Protection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Maternal Pertussis Vaccine for Newborn Protection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Maternal Pertussis Vaccine for Newborn Protection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Maternal Pertussis Vaccine for Newborn Protection significant trends, drivers, influence factors in global and regions.
6. To analyze Maternal Pertussis Vaccine for Newborn Protection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Maternal Pertussis Vaccine for Newborn Protection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Maternal Pertussis Vaccine for Newborn Protection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Maternal Pertussis Vaccine for Newborn Protection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Maternal Pertussis Vaccine for Newborn Protection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Maternal Pertussis Vaccine for Newborn Protection industry.
Chapter 3: Detailed analysis of Maternal Pertussis Vaccine for Newborn Protection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
196 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 1.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume (2020-2031)
- 1.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Maternal Pertussis Vaccine for Newborn Protection Market Dynamics
- 2.1 Maternal Pertussis Vaccine for Newborn Protection Industry Trends
- 2.2 Maternal Pertussis Vaccine for Newborn Protection Industry Drivers
- 2.3 Maternal Pertussis Vaccine for Newborn Protection Industry Opportunities and Challenges
- 2.4 Maternal Pertussis Vaccine for Newborn Protection Industry Restraints
- 3 Maternal Pertussis Vaccine for Newborn Protection Market by Company
- 3.1 Global Maternal Pertussis Vaccine for Newborn Protection Company Revenue Ranking in 2024
- 3.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Company (2020-2025)
- 3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Company (2020-2025)
- 3.4 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Company (2020-2025)
- 3.5 Global Maternal Pertussis Vaccine for Newborn Protection Company Ranking (2023-2025)
- 3.6 Global Maternal Pertussis Vaccine for Newborn Protection Company Manufacturing Base and Headquarters
- 3.7 Global Maternal Pertussis Vaccine for Newborn Protection Company Product Type and Application
- 3.8 Global Maternal Pertussis Vaccine for Newborn Protection Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Maternal Pertussis Vaccine for Newborn Protection Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Maternal Pertussis Vaccine for Newborn Protection Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Maternal Pertussis Vaccine for Newborn Protection Market by Type
- 4.1 Maternal Pertussis Vaccine for Newborn Protection Type Introduction
- 4.1.1 Whole-cell Pertussis Vaccine
- 4.1.2 Acellular Pertussis Vaccine
- 4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type
- 4.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2020-2031)
- 4.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Type (2020-2031)
- 4.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type
- 4.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2020-2031)
- 4.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type (2020-2031)
- 5 Maternal Pertussis Vaccine for Newborn Protection Market by Application
- 5.1 Maternal Pertussis Vaccine for Newborn Protection Application Introduction
- 5.1.1 Hospital
- 5.1.2 Centers for Disease Control and Prevention
- 5.1.3 Others
- 5.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application
- 5.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2020-2031)
- 5.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Application (2020-2031)
- 5.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application
- 5.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2020-2031)
- 5.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application (2020-2031)
- 6 Maternal Pertussis Vaccine for Newborn Protection Regional Sales and Value Analysis
- 6.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2020-2031)
- 6.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2020-2025
- 6.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2026-2031)
- 6.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2020-2031)
- 6.4.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region: 2020-2025
- 6.4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2026-2031)
- 6.5 Global Maternal Pertussis Vaccine for Newborn Protection Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 6.6.2 North America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 6.7.2 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 6.9.2 South America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2024 VS 2031
- 7 Maternal Pertussis Vaccine for Newborn Protection Country-level Sales and Value Analysis
- 7.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2020-2031)
- 7.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2020-2025)
- 7.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2026-2031)
- 7.4 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2020-2031)
- 7.4.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2020-2025)
- 7.4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.9.2 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.16.2 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.19.2 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Zhifei Biological
- 8.1.1 Zhifei Biological Comapny Information
- 8.1.2 Zhifei Biological Business Overview
- 8.1.3 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.1.5 Zhifei Biological Recent Developments
- 8.2 Walvax
- 8.2.1 Walvax Comapny Information
- 8.2.2 Walvax Business Overview
- 8.2.3 Walvax Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Walvax Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.2.5 Walvax Recent Developments
- 8.3 Minhai Biological
- 8.3.1 Minhai Biological Comapny Information
- 8.3.2 Minhai Biological Business Overview
- 8.3.3 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.3.5 Minhai Biological Recent Developments
- 8.4 GlaxoSmithKline
- 8.4.1 GlaxoSmithKline Comapny Information
- 8.4.2 GlaxoSmithKline Business Overview
- 8.4.3 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.4.4 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.4.5 GlaxoSmithKline Recent Developments
- 8.5 Sanofi Pasteur
- 8.5.1 Sanofi Pasteur Comapny Information
- 8.5.2 Sanofi Pasteur Business Overview
- 8.5.3 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.5.5 Sanofi Pasteur Recent Developments
- 8.6 Intravacc
- 8.6.1 Intravacc Comapny Information
- 8.6.2 Intravacc Business Overview
- 8.6.3 Intravacc Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Intravacc Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.6.5 Intravacc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Maternal Pertussis Vaccine for Newborn Protection Value Chain Analysis
- 9.1.1 Maternal Pertussis Vaccine for Newborn Protection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Maternal Pertussis Vaccine for Newborn Protection Sales Mode & Process
- 9.2 Maternal Pertussis Vaccine for Newborn Protection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Maternal Pertussis Vaccine for Newborn Protection Distributors
- 9.2.3 Maternal Pertussis Vaccine for Newborn Protection Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.